Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 5Waldenstrom Macroglobulinemia 1Recurrence 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Medulloblastoma 1Mastocytosis, Systemic 1Lymphoma, Mantle-Cell 1Liver Neoplasms 1Leukemia, Large Granular Lymphocytic 1Ependymoma 1Carcinoma, Hepatocellular 1

Interventions

Dexamethasone 17Lenalidomide 15Bortezomib 12Cyclophosphamide 7fludarabine 6carfilzomib 6Melphalan 6daratumumab 5Calcium Dobesilate 5pomalidomide 3gamma-Globulins 3fludarabine phosphate 3belantamab mafodotin 3Whole-Body Irradiation 3Trimethoprim, Sulfamethoxazole Drug Combination 3Tacrolimus 3Mycophenolic Acid 3isatuximab 2elotuzumab 2Sirolimus 2Prednisone 2Immunoglobulins, Intravenous 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Ciprofloxacin 2Amoxicillin-Potassium Clavulanate Combination 2venetoclax 1thymoglobulin 1siltuximab 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × Thalidomide × 1 year × Clear all
NCT00871013 2026-05-11

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

University of Arkansas

Phase 2 Active not recruiting
160 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡